Publication | Closed Access

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Treatment And PreventionMedicinePhase 2BLong-acting Intramuscular CabotegravirAntiviral TherapyPharmacotherapyNon-inferiority TrialChronic Viral InfectionAntiviral DrugHivPharmacology